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Abstract 
 
Purpose: Psychological responses to cancer are widely believed to affect survival. 
We investigated associations between hope, optimism, anxiety, depression, health 
utility and survival in patients starting first line chemotherapy for metastatic colorectal 
cancer. 
 
Methods: 429 subjects with metastatic colorectal cancer in a randomised controlled 
trial of chemotherapy, completed baseline questionnaires assessing: hopefulness, 
optimism, anxiety and depression and health utility. Hazard ratios (HR) and P-values 
were calculated with Cox models for overall survival (OS) and progression-free 
survival (PFS) in univariable and multivariable analyses. 
 
Results: Median follow-up was 31 months. Univariable analyses showed that OS 
was associated negatively with depression (HR 2.04, P<0.001), and positively with 
health utility (HR 0.56, P<0.001) and hopefulness (HR 0.75, P=0.013). In 
multivariable analysis, OS was also associated negatively with depression (HR 1.72, 
P<0.001), and positively with health utility (HR 0.73, P=0.014), but not with optimism, 
anxiety or hopefulness. PFS was not associated with hope, optimism, anxiety or 
depression in any analyses. 
 
Conclusions: Depression and health utility, but not optimism, hope, or anxiety were 
associated with survival after controlling for known prognostic factors in patients with 
advanced colorectal cancer.  Further research is required to understand the nature of 
the relationship between depression and survival.  If a causal mechanism is 
identified, this may lead to interventional possibilities. 
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Introduction 
Advanced colorectal cancer and its treatments are associated with physical 
symptoms and side-effects, including bowel, bladder and sexual dysfunction, pain, 
fatigue and nausea [1]. These impact on the person’s emotional and psychological 
state and adversely affect social, occupational and relationship functioning [2]. 
Adopting ‘a positive attitude’ is widely believed by patients to influence survival and is 
a way of taking control [3]. However, research about the relationship between 
psychological factors and cancer survival has yielded inconsistent results and has 
been fraught with methodological problems [4]. The main limitations have included 
samples that were small and/or unrepresentative; failure to control for major potential 
confounders such as the type of cancer, histological grade, stage of disease, 
performance status or age; and, the use poorly defined or measured psychological 
constructs. 
 
Two possible conceptualisations of “being positive” are dispositional optimism 
and hope. Dispositional optimism has been defined as the global expectation that 
good things will be plentiful in the future and bad things scarce [5]. Hopefulness is a 
related but distinct concept. Agency is the core distinction between optimism and 
hope. This sense of agency (control over one’s destiny) seems inextricably linked to 
the feeling of hope in cancer patients [6]. Hope has been defined in this study as “the 
perception that one can reach one’s desired goals” [7]. Using this definition, it may be 
expected that patients who hope for longer survival may pursue life-prolonging 
treatments more vigorously and be more vigilant about self-care activities, such as 
diet, exercise and managing treatment side effects. There is emerging research 
demonstrating a link between self-care activities and colorectal cancer survival [8]. 
Whether or not psychological state is implicated, remains to be determined. 
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The purpose of this study was to prospectively determine whether baseline 
optimism and hope were associated with overall survival (OS), progression free 
survival (PFS) and objective tumour response (OTR), after adjustment for known 
prognostic factors in patients having first line chemotherapy for advanced colorectal 
cancer in a phase III trial comparing three chemotherapy regimens. The primary 
objective, specified a priori, was to determine whether baseline measures of 
optimism and/or hope were predictive of OS, alone or after adjustment for other 
prognostic factors, including anxiety, depression, and health utility. Secondary 
objectives were to determine if baseline measures of optimism and/or hope were 
predictive of progression-free survival or objective tumour response, before and after 
adjustment for other prognostic factors. 
Materials and Methods 
This study was a prospectively planned sub-study within the phase III MAX 
trial [9]. 
Patient eligibility criteria 
Eligible patients were all those participating in the MAX trial with sufficient 
English to complete the questionnaires. The inclusion criteria were age ≥18 years, 
histological diagnosis of colorectal adenocarcinoma, unresectable metastatic 
disease, suitable for capecitabine monotherapy, Eastern Cooperative Oncology 
Group (ECOG) performance status of 0 to 2, and life expectancy of at least 12 
weeks. The exclusion criteria were: uncontrolled clinically significant cardiac disease, 
hypertension, arrhythmias or angina pectoris, acute myocardial infarction or 
cerebrovascular accident, regular use of aspirin >325 mg/day or NSAIDs, CNS 
metastases, active bleeding disorders, recent major surgical procedure, serious non-
healing wound, ulcer or bone fracture, 24-hour urinary protein >2g/24 hours, 
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pregnancy, prior history of other malignancy. All participants provided written 
informed consent and all participating sites had ethics approval for the study. 
Study design 
 In the MAX trial, participants were randomised to receive: capecitabine (C); 
capecitabine plus bevacizumab (CB); or capecitabine, bevacizumab and mitomycin C 
(CBM) [9]. This study found that adding bevacizumab to capecitabine, with or without 
mitomycin, significantly improved PFS, but not OS. Patients completed validated 
measures at baseline (before randomisation for the MAX trial) to assess optimism, 
hopefulness, anxiety, depression and health utility. Patients were followed for a 
minimum of 12 months. The median follow-up was 31 months. A previous publication 
has further methodological details [9]. 
 
Measures 
Patients were asked to complete 5 scales of hope or optimism. 
 
Optimism was measured by the Life Orientation Test (LOT) [10]. The LOT 
comprises 10 items: optimistic (3 items); pessimistic (3 items) and four filler items 
with five-point response scale (0=‘disagree strongly’ to 4=‘agree strongly’). The 
averaged total score ranged from 0 to 4 with a high score representing greater 
optimism. 
 
Hopefulness was measured by the State Hope Scale [7]. It has 6 items 
comprising 2 subscales: pathway and agency (3 items each). ‘Pathways thinking’ 
signifies one’s perceived capabilities at generating workable routes to desired goals. 
‘Agency thinking’ is the perceived capacity for initiating and maintaining the actions 
necessary to reach a goal. The response scale ranges from 0 “definitely false” to 8 
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“definitely true”. The average total score ranges from 0 (least hopefulness) to 8 
(greatest hopefulness). 
 
Anxiety and depression was assessed using the 14-item Hospital Anxiety and 
Depression Scale (HADS) with 7 items in each of the anxiety and depression 
subscales [11]. The total score for each subscale ranges from 0 (least) to 21 
(greatest) anxiety or depression respectively. A score of 11–21 was classified as a 
probable case and a score of 8–10 as a possible case. 
 
Health utility, a measure of overall quality of life suitable for health economic 
evaluations, was measured with the EuroQOL-5D (EQ-5D) comprised of 5 items and 
giving a utility score ranging from 0 (worst possible) to 1 (perfect health) [12]. 
 
Response and progression were assessed according to version 1.0 of the 
Response Evaluation Criteria in Solid Tumors (RECIST, standard international 
criteria for classifying the response to treatment of tumours evident on imaging as 
complete response, partial response, stable disease or disease progression) [13]. 
 
Statistical Analysis 
Primary analyses assessed the prognostic significance of optimism, 
hopefulness, anxiety, depression and quality of life by dichotomising variables 
according to cutpoints defined a priori. Established cutpoints were used where 
available; otherwise the median was used to divide the cohort into subgroups of 
similar size.. 
Associations with OS and PFS were determined with Cox models to calculate 
hazard ratios, 95% confidence intervals and P-values to quantify the effects of 
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variables on the hazard of death (instantaneous rate of death per unit time) in 
univariable and multivariable analyses. The Kaplan Meier method was used to 
estimate median survival times. Multivariable models were designed to determine the 
prognostic significance of the psychological factors after accounting for traditional 
prognostic factors. These models included baseline characteristics that were 
significant predictors of outcome in our main trial analyses [9], the health utility score, 
and the psychological factors. 
All statistical inferences were based on two-sided p-values of 0.05 with no 
adjustment for multiple comparisons. All analyses were performed with SAS (version 
9.2; SAS Institute, Cary, NC). The sample size was determined by the requirements 
of the randomized trial within which the study was nested, which provided over 90% 
power to detect a 33% relative reduction in the hazard for OS for a binary 
characteristic with a prevalence of 50%. 
Results 
Of the 471 participants in the MAX trial,  429 (88%) completed at least one of 
the psychological measures at baseline (Supplementary Figure 1). 
 
Baseline characteristics of the participants are summarised in Table 1 and 
were well balanced between the randomly allocated treatment groups (data not 
shown, but previously published [9]). The majority of participants had good 
performance status and good health-related quality of life. Scores were indicative of 
probable clinical depression in 5%, and of probable clinical anxiety in 12%. 
Distributions of baseline scores for the psychological factors are summarised in 
Table 2. 
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There were significant correlations among all of the psychological factors at 
baseline (see Table 3). There was a strong negative correlation between hope and 
depression, a moderate positive correlation between anxiety and depression, and 
there were moderate negative correlations between health utility and both anxiety 
and depression. 
 
Predictors of PFS and OS in univariable analysis are summarised in Table 4 
and Table 5. Health utility was the only psychological variable associated with PFS; 
hope, optimism, anxiety and depression were not significantly associated with PFS. 
Psychological predictors of OS in univariable analyses included health utility, 
depression and hopefulness, but not anxiety or optimism (Table 5). 
 
In multivariable analysis including traditional prognostic factors, the only 
psychological factors that were independent significant predictors of OS were a 
HADS depression score of 8 or higher (HR 1.72, 95% CI 12.3 to 2.38, P<.001) and 
EQ-5D health utility score of 0.8 or higher (HR 0.73, 95% CI 0.57 to 0.94, P =.014). 
Table 6 shows predictors that were significant in the multivariable model. No 
psychological factors were independently significant predictors of progression free 
survival (data not shown). 
Discussion 
After controlling for known prognostic factors, patient reported scores for 
depression and health utility were significant independent predictors of OS, whereas 
hopefulness, optimism and anxiety were not. None of these psychological factors 
were significant predictors of PFS. These findings add to the growing body of 
evidence [14-17] that both depression and quality of life assessed prior to treatment 
may influence OS after controlling for known clinical prognostic factors. 
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Chida and colleagues conducted a systematic review investigating the 
influence of psychological factors on cancer survival [14]. Whilst acknowledging 
publication bias, they concluded that stressful life events, unfavourable coping styles 
(such as helplessness-hopelessness), depression, and poor quality of life were 
related to poorer survival and higher mortality. However, others note significant flaws 
with individual studies, rendering interpretation difficult [4,18]. A systematic review of 
the influence of psychological coping and adjustment on cancer survival with more 
stringent inclusion criteria found most of this research has focused on fighting spirit 
and helplessness-hopelessness and the majority reported no significant associations 
with survival [19]. Conversely, high quality meta-analyses investigating the influence 
of baseline quality of life on cancer survival have consistently shown that quality of 
life provides additional prognostic value after adjusting for known prognostic clinical 
factors, both across cancer types [15,17] and in patients with advanced colorectal 
cancer, specifically [20,21]. A recent meta-analysis investigating depression and 
cancer survival that excluded methodologically flawed studies concluded that 
baseline depression had a small but significant influence on survival that did not 
diminish after controlling for other prognostic factors [16]. However, research about 
the influence of positive psychological states on cancer survival remains contentious 
[4]. 
 
Common methodological flaws have hindered previous attempts to determine 
the effects of psychological factors on survival [4,22]. These flaws include: small or 
heterogeneous study populations, failing to control for potential confounders either 
statistically or by sampling; follow-up that is too short; and the use of inadequately 
defined or measured psychological constructs. In contrast, the current study 
assessed psychological constructs shortly after diagnosis of metastatic disease using 
reliable and valid instruments on a tightly defined sample recruited at the same point 
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in their illness trajectory with a long follow up and statistical adjustment for known 
prognostic factors. 
 
These findings do not support the notion that optimism influences cancer 
survival. There have been inconsistent results in research investigating the 
relationship between optimism and cancer survival, most likely due to methodological 
flaws described above. In a study of patients with different types of cancer, no 
independent effects of optimism or pessimism on survival were found [23]. Another 
study examining patients with metastatic melanoma reported that optimism was 
associated with prolonged survival, however optimism was assessed by a single item 
asking the patient their perceived aim of treatment [24]. Responses to this item may 
be a reflection of communications from the doctor about treatments and prognosis, 
hence not an accurate measure of dispositional optimism. A long-term study of lung 
cancer patients found no association between pessimism and survival after adjusting 
for confounders [25]. Another study of patients with head and neck cancer found that 
dispositional optimism was predictive for 1 year survival after controlling for 
prognostic factors [26]. This study was based on a heterogeneous sample which 
included oral, pharyngeal and laryngeal cancers with stages ranging from I to IV and 
different treatment modalities. The authors acknowledge two serious limitations. First, 
sample heterogeneity and fluctuations in timing of the questionnaire administration 
with respect to the receipt of test results may have influenced optimism ratings. 
Second, potentially important predictive factors were omitted including performance 
status, socio-economic status, smoking status and biologic markers. Any of these 
may co-vary with optimism. In our previous study, we investigated the relationship 
between optimism and survival in a large, homogeneous sample of patients with 
advanced non-small cell lung cancer who were recruited at the same point in their 
illness trajectory [22]. Using validated measures and a long follow-up period, we 
found no association between pre-treatment optimism and PFS or OS after 
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controlling for the known prognostic factors. The current study displayed a similar 
level of scientific rigour. When taking into account the methodological rigor of each 
study, the weight of current evidence suggests that level of optimism does not play a 
role in cancer survival. 
 
To our knowledge, this is the first study to investigate the relationship 
between hope and cancer survival. While there was a significant relationship 
between hopefulness and OS in univariable analysis, this relationship was not 
sustained in the multivariable analysis accounting for known traditional prognostic 
factors, health utility and depression. A potential reason for this is the strong negative 
relationship between hope and depression (r=-0.63). The HADS was selected for this 
research because it does not include somatic items, such as sleep problems, fatigue, 
or appetite loss, which are all indicators of depression [27]. In a cancer population, 
these items may just reflect the symptoms and side-effects associated with advanced 
cancer and treatments. The depression subscale of HADS focuses on the anhedonic 
aspects of depression, including feelings of sadness and loss of pleasure or interest 
in activities, recognising that physical symptoms may affect these feelings [2]. High 
anhedonic depression is incompatible with feeling a strong sense of agency to 
achieve one’s goals, the definition used for hope. These constructs are clearly 
inversely related.  
 
The question is: does actively treating a patient’s depression not only improve 
their emotional well-being but might it also extend their life?. Randomized controlled 
trials testing the effects of psychotherapeutic intervention on cancer survival have 
been mixed [28]. Indeed, Coyne and colleagues presented a compelling argument to 
support their conclusion that “no randomized clinical trial designed with survival as a 
primary endpoint and in which psychotherapy was not confounded with medical care 
has yielded a positive result” [28]. They agree that improved adherence to medical 
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advice and self-care is a plausible mechanism by which depression might influence 
survival, and two trials [29,30] lend modest support to this assertion. Obviously, this 
is speculative.   
 
Placebo-controlled trials of antidepressant drugs suggest that they can improve 
depression and quality of life in patients with advanced cancer and significantly 
depressed mood or anhedonia [31] but not in those with milder symptoms of 
depression [32]. Survival analyses in these trials did not suggest any benefit of 
antidepressant drugs. To date, research, including this study, only demonstrate an 
association between depression and survival not that depression influences survival.  
Further research is required to understand the nature of the relationship between 
depression and survival.  If there appears to be a causal link, this may lead to the 
potential for intervention. 
 
The main limitation of this study is its observational design: this allows strong 
inferences about association, but not about causality. While eligibility criteria was 
tight and a number of prognostic indicators were controlled for in the analyses, there 
was still the potential for the baseline assessment to be confounded with prognosis. 
A patient’s general health status or their physician’s communication relating to 
prognosis or potential treatment efficacy may have influenced responses to 
psychological assessments.   In addtion, our findings are confined to patients having 
first line chemotherapy for colorectal cancer. Confirmation of our findings in other 
settings with alternative instruments is needed. 
Conclusions 
This is the largest and most methodologically robust prospective study of the 
relationship between hope, optimism and survival in advanced cancer patients. We 
used instruments for measuring hope, optimism and depression which are the best 
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validated and available for the cancer setting in a large, homogeneous sample of 
people with metastatic colorectal cancer. The concept, instruments, data collection 
and analysis were planned a priori. The findings support previous research which 
suggests that lower levels of depression and higher quality of life predict longer OS 
independent of other known prognostic factors. This relationship did not hold for 
progression free survival. Optimism was not associated with OS or PFS. Hopefulness 
was negatively correlated with depression, and was associated with OS when 
assessed alone but not after accounting for other known prognostic factors. 
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Table 1: Baseline characteristics (N=429) 
 
Total 
n= 429 
Performance status (ECOG)  
0 245 (57%) 
1 162 (38%) 
2 22 (5%) 
Age in years (median, range) 67 (32-86) 
Male 271 (63%) 
Primary tumor resected 338 (79%) 
Liver metastases 324 (76%) 
Prior Radiotherapy 55 (13%) 
Prior Chemotherapy 93 (22%) 
  
EQ-5D utility  
 < 0.8 242 (57%) 
 ≥ 0.8 180 (43%) 
HADS anxiety  
 < 8 291 (69%) 
 8 - 10 80 (19%) 
 11 - 15 39 (9%) 
 16+ 11 (3%) 
HADS depression  
 < 8 360 (86%) 
 8 - 10 40 (10%) 
 11 - 15 15 (4%) 
 16+ 6 (1%) 
LOTS optimism  
 < 2.5 150 (35) 
 ≥ 2.5 274 (65) 
SHS Hopefulness  
 < 6 160 (38) 
 ≥ 6 263 (62) 
  
Data are n (%) or median (range) 
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Table 2: Baseline scores for psychological factors. 
Variable N Mean Median Q1 Q3 Min Max 
EQ-5D utility (0 to 1) 422 0.75 0.80 0.69 0.88 0 1 
HADS anxiety (0 to 21) 421 5.8 5 3 8 0 20 
HADS depression (0 to 21) 421 3.8 3 1 6 0 18 
LOTS optimism (0 to 4) 424 2.7 2.7 2.2 3.2 0.7 4 
SHS Hopefulness (0 to 8) 423 6.0 6.3 5.2 7.2 1.0 8 
Notes: Q1 & Q3 are the first and third quartiles, i.e. 25% of observed values are 
below Q1 and 25% are above Q. Between Q1 and Q3 are the ‘middle fifty.’ 
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Table 3: Spearman rank correlations among psychological factors at baseline. 
 Optimism Anxiety Depression EQ-5D utility 
Hope 0.34 -0.43 -0.63 0.39 
Optimism  -0.35 -0.35 0.22 
Anxiety   0.51 -0.45 
Depression    -0.48 
p < 0.0001 for all correlations 
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Table 4: Progression Free Survival - Univariable models 
NOTE: the comparator for each row is the level indicated first in brackets, except for 
treatment .  
 
With 
characteristic Median survival time (months) 
 
 
Variable n (%) 
without 
characteristic 
with 
characteristic 
HR (95% CI) with 
characteristic P 
Treatment      
C (reference) 145 (33)  6   
CB 146 (33)  9 0.59 (0.46, 0.75) <0.001 
CBM 147 (34)  8 0.56 (0.44, 0.71) <0.001 
Conventional prognostic factors      
Age (<60 vs. 60+) 321 (73) 8 7 0.94 (0.76, 1.18) 0.608 
Gender (F vs. M) 277 (63) 7 7 0.94 (0.76, 1.15) 0.530 
PS (0 vs. 1-2) 186 (42) 8 6 1.57 (1.29, 1.92) <0.001 
Liver metastases (N vs. Y) 331 (76) 7 7 1.18 (0.94, 1.48) 0.158 
Haemoglobin (12+ vs. <12) 146 (33) 7 7 1.19 (0.97, 1.46) 0.097 
ALP (<140 vs. 140+) 162 (37) 8 6 1.45 (1.19, 1.78) <0.001 
CEA (<30 vs. 30+) 205 (48) 7 7 1.28 (1.05, 1.57) 0.014 
Primary Tumor Resected (N vs. Y) 346 (79) 7 8 0.71 (0.56, 0.90) 0.004 
Bilirubin (<14 vs. 14+) 79 (18) 7 7 1.22 (0.95, 1.57) 0.116 
Number of metastatic sites (<2 vs. 
2+) 
181 (41) 8 7 
1.32 (1.08, 1.61) 
0.007 
Patient rated measures      
EQ-5D utility (<0.8 vs. 0.8+) 180 (43) 7 8 0.76 (0.62, 0.93) 0.007 
HADS anxiety (<8 vs. 8+) 130 (31) 7 7 1.05 (0.85, 1.32) 0.616 
HADS depression (<8 vs. 8+)  61 (15) 7 6 1.21 (0.91, 1.59) 0.202 
LOTS optimism (<2.5 vs. 2.5+) 274 (65) 7 7 1.03 (0.84, 1.27) 0.786 
SHS Hopefulness (<6 vs. 6+) 263 (62) 7 8 0.90 (0.73, 1.10) 0.312 
Notes: HADS scores of 8 or more signifying possible or probable depression 
or anxiety; optimism scores of 2.5 or more signifying higher optimism and 
hopefulness scores of 6 or more signifying higher hopefulness. C – capecitabine, CB 
– capecitabine with bevacizumab, CBM – capecitabine with bevacizumab and 
mitomycin, PS – performanace status, ALP – alkaline phosphatase, CEA – 
carcinoembryonic antigen.
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Table 5: Overall survival - Univariable models 
NOTE: the comparator is the level indicated first in the brackets except for Treatment  
 
With 
characteristic Median survival time (months)  
Variable n (%) 
without 
characteristic 
with 
characteristic HR (95% CI) P 
Treatment      
C (reference) 145 (33)  19 1.00  
CB 146 (33)  20 0.79 (0.61, 1.03) 0.078 
CBM 147 (34)  16 0.97 (0.75, 1.26) 0.841 
Conventional prognostic factors      
Age (<60 vs. 60+) 321 (73) 21 17 1.28 (1.00, 1.64) 0.047 
Gender (F vs. M) 277 (63) 17 20 0.86 (0.69, 1.07) 0.179 
PS (0 vs. 1-2) 186 (42) 22 13 2.09 (1.68, 2.60) <0.001 
Liver metastases (N vs. Y) 331 (76) 22 17 1.20 (0.93, 1.56) 0.157 
Haemoglobin (12+ vs. <12) 146 (33) 21 13 1.69 (1.35, 2.11) <0.001 
ALP (<140 vs. 140+) 162 (37) 22 12 1.87 (1.50, 2.32) <0.001 
CEA (<30 vs. 30+) 205 (48) 20 16 1.24 (1.00, 1.54) 0.055 
Neutrophils (<8 vs. 8+) 346 (79) 20 9 1.89 (1.41, 2.52) <0.001 
Prior Radiotherapy (N vs. Y) 79 (18) 18 16 
1.28 (0.94, 1.74) 
0.125 
Primary Tumor Resected (N vs. Y) 181 (41) 13 20 0.62 (0.48, 0.80) 
 
<0.001 
Patient rated measures      
EQ-5D utility (<0.8 vs. 0.8+) 180 (43) 16 23 0.56 (0.45, 0.71) <0.001 
HADS anxiety (<8 vs. 8+) 130 (31) 19 17 1.06 (0.84, 1.34) 0.634 
HADS depression (<8 vs. 8+) 61 (15) 20 11 2.04 (1.52, 2.70) <0.001 
LOTS optimism (<2.5 vs. 2.5+) 274 (65) 17 18 0.98 (0.78, 1.23) 0.871 
SHS Hopefulness (<6 vs. 6+) 263 (62) 15 20 0.75 (0.60, 0.94) 0.013 
 
C – capecitabine, CB – capecitabine with bevacizumab, CBM – capecitabine 
with bevacizumab and mitomycin, PS – performanace status, ALP – alkaline 
phosphatase, CEA – carcinoembryonic antigen. 
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Table 6: Overall Survival - multivariable model including traditional factors significant 
in the trial’s original analysis (N= 407) 
Variable Characteristic No. (%) HR 95% CI for HR P 
Treatment group C 134 (33) 1.00   
 CB  136 (33) 0.80 (0.60,1.05) 0.107 
 CBM  137 (34) 0.94 (0.72,1.23) 0.662 
Performance status ≥ 1 172 (42) 1.62 (1.29,2.05) <0.001 
Neutrophils (x109/L) ≥ 8 58 (14) 1.33 (0.96,1.85) 0.083 
Alkaline phosphatase (U/L) ≥ 140 151 (37) 1.65 (1.30,2.09) <0.001 
Prior radiotherapy Yes 321 (79) 1.54 (1.10,2.15) 0.011 
Primary Tumor Resected Yes 321 (79) 0.79 (0.61,1.03) 0.086 
HADS Depression ≥ 8 58 (14) 1.72 (1.23, 2.38) <0.001 
EQ-5D utility ≥ 0.8 173 (43) 0.73 (0.57,0.94) 0.014 
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 Supplementary Figure 1: Consort Diagram 
 
 
 
 
 
 
 
 
 
 
 
Notes: There were 438 patients who completed at least one baseline QoL for EQ-5D, 
HADS, LOT or SHS. There were 429 patients who completed at least one of HADS, LOT 
or SHS. The numbers of patients completing each questionnaire were: HADS = 421, 
LOT = 424, SHS = 423 
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